1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends

Global Biosimilar Market Trends & Opportunities: 2015 Edition

  • January 2015
  • 80 pages
  • Daedal Research
Report ID: 2635506

Summary

Table of Contents

Search Inside

Scope of the Report

The report titled “Global Biosimilar Market: Trends & Opportunities (2015 Edition)” analyzes the global biologics market, with exhaustive discussion on demand of Biosimilars with increase in patent expiry of innovator drugs. The key market challenges recognized by the analysts and the major trends biosimilar market are presented in the report. Further, key manufacturers of Biosimilars like Sandoz, Teva, Hospira and Dr. Reddy’s Lab are profiled in the report.

Product Coverage

- Recombinant Glycosylated Biosimilars (EPO,mAb,Follitropin)
- Humira, Enbrel, Remicade, Herceptin
- Recombinant Non-Glycosylated Biosimilars (Insulin,G-csf,Interferons,hGh)

Company Coverage

- Sandoz(Novartis)
- Hospira
- Teva
- Dr. Reddy’s Lab

Executive Summary

Rising budgetary pressures to reduce healthcare expenditures, patent expiries of blockbuster drugs, growing demand for cost-effective alternatives, increasing aging population, conductive government initiatives and rising incidences of various diseases are significant factors that are responsible for the growth of global biosimilar market (2013 to 2018). On the other hand stringent regulatory environment in some countries, high manufacturing complexities, costs, and presence of low priced generic drugs and high-entry barriers are considered to hinder the market growth. Emerging pharmaceutical market and less stringent government regulatory frameworks in few countries can provides some of the major opportunities for biosimilars market. In addition, increased collaboration between manufacturing companies and outsourcing of biosimilar products are key trends for biosimilars market.

The biosimilar products market is segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. Globally there are 280 biosimilars in pipeline and their clinical trials are increasing at a rate of 20% annually.

The report titled “The Global Biosimilar Market: Trends & Opportunities (2014-2018)” provides an in-depth analysis of the growing Biosimilar Market with detailed analysis of market sizing and growth, market share and economic impact of the industry. The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall Biosimilars industry has also been forecasted for the period 2014-18, taking into consideration the previous growth patterns, the growth drivers and the current and future trends. Further, key players of the industry like Sandoz, Teva, Hospira and Dr. Reddy’s Lab are profiled.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Veronica helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Biosimilars Market Access in the U.S.

  • $ 7500
  • Industry report
  • March 2017
  • by Datamonitor Healthcare

The route to a formal US regulatory pathway for biosimilar approval was established with the creation of the Biologics Price Competition and Innovation Act of 2010. However, it took five more years fo ...

Biosimilars Market Access in Psoriasis

  • $ 7500
  • Industry report
  • March 2017
  • by Datamonitor Healthcare

Tumor necrosis factor (TNF)-alpha inhibitors Enbrel, Humira, and Remicade have long held dominant positions in the psoriasis market; however, these market leaders face patent expirations and consequent ...

Biosimilar Insulin Market Access

  • $ 5000
  • Industry report
  • March 2017
  • by Datamonitor Healthcare

Overview Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure. The launch of the biosimila ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.